Company Launches Internships at Manufacturing Facility in Leuna, Germany to Cultivate Future Leaders in the Medical Cannabis Industry EDMONTON, AB , Jan. 10, 2025 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is pleased to announce the launch of an internship program at Aurora's leading EU-GMP facility in Leuna, Germany . In partnership with Erfurt... Read More

The collaboration aims to broaden access of premium medical cannabis products to Australian patients EDMONTON, AB , Dec. 17, 2024 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is pleased to announce a distribution partnership between The Entourage Effect and MedReleaf Australia. The Entourage Effect provides comprehensive distribution and support services... Read More

Canada's Largest Medical Cannabis Company Continues to Offer Greater Choice for Patients EDMONTON, AB , Nov. 26, 2024 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces developments in cannabis science from Aurora's world class research and genetics... Read More

Introduces New Products and Flavours across Greybeard, San Rafael '71 and Tasty's brands EDMONTON, AB , Nov. 20, 2024 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is excited to announce its latest lineup of innovations from Greybeard, San Rafael '71 and... Read More

Record Adjusted EBITDA 1 of $10.1 Million , a YoY increase of 210% Quarterly Net Revenue 1 up 29% YoY to $81.1 Million , with 41% growth in Global Medical Cannabis Re-Affirms Target of Positive Free Cash Flow 1 in the Quarter Ending December 31, 2024 Maintains Strong Balance Sheet with ~$152 Million of Cash and a Debt-Free Cannabis Business 2 EDMONTON, AB , Nov. 6, 2024 /CNW/ - Aurora Cannabis Inc. (the "Company" or... Read More

EDMONTON, AB , Oct. 24, 2024 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today announced today that it has scheduled a conference call to discuss the results for its second quarter 2025 on Wednesday, November 6, 2024 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time . The Company will report its financial results... Read More

EDMONTON, AB , Oct. 16, 2024 / CNW/ - Aurora Cannabis Inc., (NASDAQ: ACB) (TSX: ACB) – the Canadian based global leader in medical cannabis, in conjunction with MedReleaf Australia, is pleased to announce an enhanced product range of premium medical cannabis oil in Australia . This expansion reinforces Aurora's dedication to providing high-quality, innovative cannabis solutions to patients around the world. Now available for... Read More

Research Project designed to validate breeding genetics connected with fruity aroma, a key patient and consumer preference trait, with positive impact on future innovation EDMONTON, AB , Oct. 2, 2024 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) –—the Canadian based leading global medical cannabis company, today announced a research grant provided to the University of British Columbia (UBC) by Genome British Columbia... Read More

Outgoing Chairman Ron Funk appointed Lead Independent Director, as part of Board leadership transition EDMONTON, AB , Sept. 20, 2024 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora" ) (NASDAQ: ACB) (TSX: ACB), a leading Canada -based global medical cannabis company, today announced the appointments of CEO Miguel Martin to the additional role of Executive Chairman and outgoing Chairman Ron Funk as Lead Independent... Read More

EDMONTON, AB , and STAMFORD, Conn. , Sept. 9, 2024 /CNW/ - Aurora Cannabis Inc. ("Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canadian-based global medical cannabis company, and Vectura Fertin Pharma, Inc., an innovator in wellness and healthcare, are pleased to announce the launch of the newly developed Luo CBD lozenge. The high-quality CBD lozenge was developed by Vectura Fertin Pharma and adheres to stringent safety,... Read More

EDMONTON, AB , Aug. 12, 2024 /CNW/ - Aurora Cannabis Inc . (the "Company" or "Aurora" ) (NASDAQ: ACB) (TSX: ACB), a leading Canada -based global medical cannabis company, is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the " Meeting ") held Friday August 9, 2024 by virtual webcast. The total number of shares represented by shareholders present in person (virtually) and... Read More

Delivers Positive Free Cash Flow 1 of $6.5 Million Increases Total Quarterly Net Revenue 1 by 12% YoY to $83.4 Million , Record Net Revenue 1 of $47.2 Million in Global Medical Cannabis Generates Adjusted EBITDA 1 of $4.9 Million , a YoY increase of 87% Ends the Fiscal Quarter with a Debt-Free Cannabis Business 2 and a Cash Position of ~$182 Million EDMONTON, AB , Aug. 7, 2024 /CNW/ - Aurora Cannabis Inc. (the "Company" or... Read More

Collaboration will initially see launch of a new CBD lozenge from Cogent International, a Vectura Fertin Pharma subsidiary, on Aurora's Canadian medical cannabis patient platform Following successful launch of CBD lozenge, the collaboration will explore the potential to launch Vectura Fertin Pharma's future medical cannabis portfolio in Canada EDMONTON, AB , and STAMFORD, Conn. , Aug. 1, 2024 /CNW/ - Aurora Cannabis Inc . ("... Read More

NASDAQ | TSX: ACB EDMONTON, AB , July 29, 2024 /CNW/ - Aurora Cannabis Inc . (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada -based global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its first quarter 2025 on Wednesday, August 7, 2024 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time . The Company will report its financial results for... Read More

Company's Long-Standing Investment in the Region Continues with Enhanced Local Production and Domestic Cultivar Research EDMONTON, AB , July 25, 2024 /CNW/ - Aurora Cannabis Inc. (the " Company " or " Aurora ") (NASDAQ: ACB) (TSX: ACB), a leading Canadian-based global medical cannabis company, has been granted two licenses by the Federal Institute for Drugs and Medical Devices (BfArM) under Germany's new Medical Cannabis Act... Read More

Delivers Record Annual Adjusted EBITDA 1 of $12.8 Million Q4 Represents the Sixth Consecutive Quarter of Positive Adjusted EBITDA 1 Increased Total Quarterly Net Revenue 5% YoY to $67.4 Million , Global Medical Cannabis Net Revenue 1 Grew by 20% YoY to $45.6 Million Ended the Fiscal Year with a Cash Position of ~$180 Million with Cannabis Business Debt-Free 2 Re-Affirms Target of Reaching Positive Free Cash Flow 1 by... Read More

EDMONTON, AB , June 7, 2024 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada -based global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its fourth quarter and fiscal year 2024 on Thursday, June 20, 2024 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time . The Company will report its financial results for the... Read More

Canada's Leading Medical Cannabis Company and MedReleaf Australia Launch Innovative Resin Cartridges to Offer Greater Choice for Patients EDMONTON, AB , June 5, 2024 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) – the Canadian based leading global medical cannabis company, in conjunction with MedReleaf Australia, is excited to announce the launch of its premium 1.2g resin cartridges in Australia . This expansion... Read More

Newly created directorship to be filled by Rajesh Uttamchandani EDMONTON, AB , May 15, 2024 /CNW/ - Aurora Cannabis Inc. (the " Company " or " Aurora ") (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today the appointment of Rajesh Uttamchandani to the Company's Board of Directors (the " Board "), effective today. Mr. Uttamchandani joins the Board with notable expertise in... Read More

Canada's Leading Medical Cannabis Company Launches Premium Products Redefining Patient Care EDMONTON, AB , May 8, 2024 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) the Canadian based leading global medical cannabis company, is proud to announce the arrival of Aurora branded medical cannabis products to the New Zealand... Read More

Canada's Leading Medical Cannabis Company and MedReleaf Australia Launch Innovative Product to Offer Greater Choice for Patients EDMONTON, AB , April 30, 2024 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) – the Canadian based leading global medical cannabis company, in conjunction with MedReleaf Australia, is pleased... Read More

The Expected De-scheduling of Cannabis to Fuel Expansion of the Medical Cannabis Market in Germany EDMONTON, AB , April 1, 2024 /PRNewswire/ -- Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) – a Canadian based leading global medical cannabis company, applauds the German government's final endorsement of cannabis legalization, marking a significant step forward in bolstering patient access to medical cannabis with the official... Read More

Canada's Leading Medical Cannabis Company and MedReleaf Australia Launch Innovative Product to Offer Greater Choice for Patients EDMONTON, AB , March 4, 2024 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) – The Canadian based leading global medical cannabis company, together with subsidiary company, MedReleaf Australia,... Read More

EDMONTON, AB , Feb. 29, 2024 /CNW/ - Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canada -based leading global medical cannabis company, today announced that it has repaid an aggregate of approximately $7.2 million ( US$5.3 million ), representing the final payment on the principal amount of its convertible senior notes ("Notes") at a total cash cost of $7.4 million ( ~US$5.5 million ),... Read More

Partnership will empower UK patients with valuable information and guidance critical to a successful cannabis experience EDMONTON, AB , Feb. 28, 2024 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, today announced the partnership of Aurora Medicine UK Ltd with Script Assist, a cutting-edge medical cannabis prescription platform in the UK. Designed to support... Read More

EDMONTON, AB , Feb. 20, 2024 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora" ) (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, is pleased to announce today that Simona King , a former executive of Bristol Myers-Squibb, a leading multinational pharmaceutical company, has been appointed as Chief Financial Officer of the Company, effective February 21, 2024 . Ms. King brings over 25... Read More

Re-Affirms Commitment to Achieving Positive Free Cash Flow 1 This Calendar Year, Delivers Fifth Consecutive Quarter of Positive Adjusted EBITDA 1 Aurora Becomes the Largest Global Medical Cannabis Company in Nationally Legal Markets Following the Acquisition of MedReleaf Australia Strong YoY Growth of 41% in High Margin International Net Cannabis Revenue 1 Cash position of over $200 Million as of Quarter Close, Remaining... Read More

Aurora becomes the largest global medical cannabis company operating in nationally legal markets. MedReleaf Australia holds the #2 position in medical cannabis within the rapidly growing ~AUD$400 million 1 Australian market. Transaction is expected to be immediately accretive to Adjusted EBITDA 2 and accelerate the Company's plan for Positive Free Cash Flow 2 generation in calendar 2024. EDMONTON, AB , Feb. 8, 2024 /CNW/ -... Read More

Re-affirms expectation of positive annual Adjusted EBITDA 1 for fiscal 2024 and Positive Free Cash Flow 1 generation in calendar 2024 Announces Intention to Consolidate Common Shares Q3 2024 Investor Conference call scheduled for February 8, 2024 at 8:00 a.m. Eastern Time EDMONTON, AB , Jan. 31, 2024 /CNW/ - Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical... Read More

Available at launch exclusively to Aurora's veteran patients, new products span THC, CBD and CBG offerings to meet the discerning taste, experience and product variety patients seek EDMONTON, AB , Jan. 24, 2024 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company,... Read More

Delivers Record Positive Adjusted EBITDA 1 of $ 3.4 Million Quarterly Net Revenue 1 rose 30% YoY to $63.4 Million ; Strong Growth of 42 % in Global Medical Cannabis Net cash position of over $200 Million , Expects to Repay the Remaining US$5.3 Million Balance of Convertible Senior Notes in February 2024 Re-Affirms Target of Achieving Positive Free Cash Flow 1 in Calendar Year 2024 EDMONTON, AB , Nov. 9, 2023 /CNW/ - Aurora... Read More

EDMONTON, AB , Oct. 26, 2023 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, announced today that it has scheduled a conference call to discuss the results for its second quarter fiscal year 2024 on Thursday, November 9, 2023 at 5:00 p.m. Eastern Time | 3:00 p.m. Mountain Time . The Company will report its financial results for the second... Read More

Company affirms commitment to enforce and defend intellectual property rights EDMONTON, AB , Oct. 24, 2023 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, today announced the company and WILLOW BIOSCIENCES, INC. ("Willow") have successfully completed a confidential settlement ‎resolving the ongoing patent litigation between the two parties in Canada . "We are pleased... Read More

Intends to Repay Remaining Convertible Debt Balance, Saving Almost C$2 Million in Annual Interest Payments EDMONTON, AB , Oct. 3, 2023 /CNW/ - Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, today announced the closing of its previously announced bought deal offering of 53,187,500 common shares of the Company (the "Offered Securities") at a price... Read More

EDMONTON, AB , Sept. 28, 2023 /CNW/ - Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, today announced that it has entered into an agreement pursuant to which Canaccord Genuity has agreed to buy, on a bought deal basis, 46,250,000 common shares of the Company (the "Offered Securities") at a price of C$0 .73 per Offered Security (the "Offering... Read More

New brand promises great product and taste. First lineup includes flavour packed 50% THC pre-rolls and 1,000mg vapes EDMONTON , AB , Sept. 19, 2023 /CNW/ - Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, is launching a bold new brand, TASTY'S , to the Canadian adult market,... Read More

EDMONTON, AB , Sept. 19, 2023 /CNW/ - Aurora Cannabis Inc. ("Aurora" or the "Company") ( NASDAQ : ACB) (TSX : ACB ), the Canadian company opening the world to cannabis, today announced that it has received approval to transfer the listing of its common shares (the "Shares") from the Nasdaq Global Select Market to the Nasdaq Capital Market (the "Transfer"). The Transfer became effective at the opening of business on September... Read More

Proceeds from Strain for Heroes sales to support veteran organizations across Canada EDMONTON, AB , Sept. 7, 2023 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, today announced the launch of Honour, a new cannabis cultivar designed for veterans, by veterans and the second offering from Aurora's Strain for Heroes portfolio. Five per cent of net profits from... Read More

Full-Spectrum, Single-Source 3% CBD Oil will be First Product to Launch EDMONTON, AB , Sept. 6, 2023 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis and Canada's largest medical cannabis company, today announced an expansion of its hemp-derived CBD portfolio into Brazil . In partnership with Herbarium, the leading Brazilian company in herbal medicine, Aurora will... Read More

EDMONTON, AB , Aug. 14, 2023 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora" ) (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, is pleased to announce the voting results from its Annual General Meeting of Shareholders (the " Meeting ") held today, Monday, August 14, 2023 by virtual webcast. The total number of shares represented by shareholders present in person and by proxy at the... Read More

Achieves Quarterly Net Revenue 1 of $75.1 Million ; Strong YoY Growth Across All Business Units; Global Medical Cannabis +14%, Consumer Cannabis +5% , Plant Propagation +12% Delivers Third Sequential Quarter of Positive Adjusted EBITDA 1 , Supported by Bevo's Record Quarterly Revenue Cash Used in Operating Activities Reduced by $15.5 Million YoY, Re-Affirms Target of Positive Free Cash Flow in Calendar Year 2024 EDMONTON, AB... Read More

Sourdough Shortcuts are now infused with live resin THCA diamonds, adding a super high potency offering to Aurora's portfolio of medical products EDMONTON, AB , Aug. 1, 2023 /CNW/ - Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, has launched its first high-potency infused pre-roll... Read More

EDMONTON , AB , July 27, 2023 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, announced today that it has scheduled a conference call to discuss the results for its first quarter fiscal year 2024 on Thursday, August 10, 2023 at 5:00 p.m. Eastern Time | 3:00 p.m. Mountain Time . The Company will report its financial results for this period... Read More

Your vote is important no matter how many shares you own. Vote today. Shareholders who have questions or need assistance with voting their shares should contact Aurora Cannabis Inc.'s strategic advisor and proxy solicitation agent, Laurel Hill Advisory Group, by telephone at 1-877-452-7184 or by email at assistance@laurelhill.com . EDMONTON, AB , July 19, 2023 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:... Read More

NASDAQ | TSX: ACB Achieves Second Sequential Quarter of Positive Adjusted EBITDA 1 Net Revenue Reaches $64 Million , Increasing 4% Sequentially and 27% YoY; Driving Adjusted Gross Profit 1 of $30.6 Million Balance Sheet Remains Strong With a Cash Position of ~ $230 Million Cash on Hand with ~$80 Million of Convertible Notes Remaining Outstanding Clear Path to Achieve Positive Free Cash Flow by the End of Calendar Year 2024... Read More

EDMONTON, AB , June 7, 2023 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, announced today that it has scheduled a conference call to discuss the results for its third quarter and full fiscal year 2023 on Wednesday, June 14, 2023 at 8:15 a.m. Eastern Time | 6:15 a.m. Mountain Time . The Company will report its financial results for the... Read More

Additions to product lineup include snackable edibles, bold flavoured vapes, signature hash and an original flower strain EDMONTON, AB , June 6, 2023 /CNW/ - Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, is launching a fresh lineup of innovative products, available to patients on Aurora Medical and consumers, at retailers across the country this summer. The company's... Read More

EDMONTON, AB , May 30, 2023 /CNW/ - Aurora Europe GmbH, a subsidiary of Aurora Cannabis Inc . (NASDAQ: ACB) (TSX: ACB), and Ethypharm are pleased to announce that they have once again been selected by the French General Directorate of Health (DGS) as exclusive suppliers of dried medical cannabis flower until the end of the French trial period. The trial has recently been extended until March 2024 . "We are delighted to have... Read More

EDMONTON, AB , April 28, 2023 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, and a leading manufacturer and supplier of dried flower for medical patients worldwide, today announced the expansion of its portfolio in Germany with the launch of two new cannabis flower products for patients. Pedanios 27/1 FRG CA and Pedanios 29/1 SRD CA are... Read More

EDMONTON, AB , April 26, 2023 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, today announced the launch of a new tracking program designed to support and empower cannabis patients on their wellness journey. Alongside the advice of a healthcare professional, Aurora patients can use the award-winning Strainprint ® App journal to track their medical cannabis journey by... Read More

New additions to lineup include two original cultivars from Aurora's breeding program, strain-specific gummies, aromatic vapes and terpy diamonds & sauce EDMONTON, AB , April 25, 2023 /CNW/ - Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, today announced a fresh lineup of... Read More

EDMONTON, AB , April 24, 2023 /CNW/ - Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, today announced that it has repurchased an aggregate of approximately $22.3 million ( US$16.6 million ) principal amount of its convertible senior notes ("Notes") in multiple transactions since the start of April 2023 at a total cash cost, including accrued... Read More

Available through MedReleaf's Concession Scheme, doctors and patients will have more freedom in choosing their cannabis medication EDMONTON, AB , April 12, 2023 /CNW/ - Aurora Cannabis Inc . (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, and MedReleaf Australia today announced the launch of IndiMed Tempo 26, a range of new higher THC dried cannabis products for qualified patients under the... Read More

EDMONTON, AB , March 30, 2023 /CNW/ - Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, today announced that it has repurchased an aggregate of approximately $46.6 million ( US$34.3 million ) principal amount of its convertible senior notes ("Notes") at a total cost, including accrued interest, of $45.6 million ( US$33.6 million ) in cash, saving... Read More

EDMONTON, AB , March 24, 2023 /CNW/ - Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, today announced receipt of a notification letter (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") dated March 24, 2023 , advising that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) as the bid price of the Company's... Read More

EDMONTON, AB , March 17, 2023 /CNW/ - Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, today announced it has filed a new preliminary short form base shelf prospectus (the "Base Shelf Prospectus") with securities regulators in each of the provinces of Canada , except Quebec . The Base Shelf Prospectus, together with a corresponding registration... Read More

Proceeds from Valour sales to support veteran organizations across Canada EDMONTON, AB , March 2, 2023 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, today announced the launch of Valour, a new cannabis cultivar designed for veterans, by veterans. Five per cent of net... Read More

Canada's leading medical cannabis provider and Australia's preeminent medical cannabis supplier to bring three new premium strains to Australian patients EDMONTON, AB , Feb. 22, 2023 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, and MedReleaf Australia today announced the launch of CraftPlant, a new medical cannabis brand for patients in the Australian market. The... Read More

Cannabis Revenues Up ~20% from Fiscal Q1 2023, Net Revenue 1 of $61.7 Million Achieves Positive Adjusted EBITDA 1 in Line with Prior Guidance Delivers ~$340 Million in Annualized Cost Savings Since February 2020 Balance Sheet Remains in Net Cash Position, Among Strongest in Industry; Debt Reduction of ~$302 Million in CY 2022 EDMONTON, AB , Feb. 9, 2023 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB)... Read More

EDMONTON, AB , Jan. 26, 2023 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today that it has scheduled a conference call to discuss the results for its second quarter fiscal year 2023 on Thursday, February 9, 2023 at 5:00 p.m. Eastern Time | 3:00 p.m. Mountain Time . The Company will report its financial results... Read More

EDMONTON, AB , Jan. 4, 2023 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today that the Company has closed the sale of its Aurora Polaris facility for gross proceeds of approximately $15 million , previously announced to be closing under the Company's ongoing transformation program. Aurora's balance sheet... Read More

EDMONTON, AB , Dec. 9, 2022 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, is excited to announce its Greybeard Cannabis Co. brand has won KIND Magazine's 'Best Diamonds of the Year' award, as voted by hundreds of budtenders, store managers and independent cannabis retail owners across Canada . Greybeard is known for its... Read More

Balance Sheet Remains in Net Cash Position, Further Strengthened with Accretive Debt Reduction EDMONTON, AB , Dec. 5, 2022 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced that it has repurchased an aggregate of approximately $102.5 million ( US$76.1 million ) principal amount of its convertible senior notes... Read More

NASDAQ | TSX: ACB EDMONTON, AB , Nov. 14, 2022 /CNW/ - Aurora Cannabis Inc. (the " Company " or " Aurora ") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the " Meeting ") held today, Monday, November 14, 2022 by virtual webcast. The total number of shares represented by... Read More

Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today that it has scheduled a conference call to discuss the results for its first quarter fiscal year 2023 on Thursday, November 10, 2022 at 5:00 p.m. Eastern Time | 3:00 p.m. Mountain Time . The Company will report its financial results for the first quarter fiscal year... Read More

Aurora medical patients now have expanded access to company's full portfolio of adult-use cannabis brands Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced a new and unprecedented fall lineup of cannabis products. New flower products include three unique and proprietary strains from Aurora's esteemed breeding program: Electric Honeydew , Ultra Grape... Read More

Balance Sheet Remains in Net Cash Position, Further Strengthened with Accretive Debt Reduction Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced that it has repurchased an aggregate of approximately $31.3 million ( US$23.0 million ) principal amount of its convertible senior notes ("Notes") at a total cost, including... Read More

Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today that it has scheduled a conference call to discuss the results for its fourth quarter and full fiscal year 2022 on Tuesday, September 20, 2022 at 5:00 p.m. Eastern Time | 3:00 p.m. Mountain Time . The Company will report its financial results for the fourth quarter and... Read More

Long Term Investment Expected to Deliver Aurora Immediate Positive Cash Flow Aurora acquires a controlling interest in Bevo; one of the largest suppliers of propagated vegetables and ornamental plants in North America with proven track record of profitability Bevo will continue to be run by existing management team; robust growth plan includes use of Aurora Sky for ornamental plant cultivation and for vegetable propagation... Read More

Aurora Further Strengthens Balance Sheet with Accretive Debt Reduction Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced that it has repurchased an aggregate of approximately $25.3 million ( US$20 million ) principal amount of its convertible senior notes ("Notes") at a total cost, including accrued interest, of $24.3... Read More

Over-Allotment Option Exercised in Full Strengthened Balance Sheet Eliminates Need to Access the ATM Facility in the Near Future Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, has announced today the closing of its previously announced bought deal offering of units of the Company (the "Units") for gross proceeds of approximately... Read More

Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, has announced today that it has amended the terms of its previously announced bought deal financing. Under the amended terms, a syndicate of underwriters led by Canaccord Genuity and BMO Capital Markets, have agreed to buy on a bought deal basis 61.2 million units of the Company (the... Read More

Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today has announced today that it has entered into an agreement with a syndicate of underwriters led by Canaccord Genuity and BMO Capital Markets, under which the underwriters have agreed to buy on bought deal basis 51.1 million units of the Company (the "Units"), at a price of... Read More

State-of-the-art facility readying first delivery of medical grade cannabis for German patients Aurora Cannabis Inc . (the " Company " or " Aurora ") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the company has received EU-GMP certification for its state-of-the-art medical cannabis production facility in Germany . As a leading manufacturer of medical cannabis... Read More

Increasing Original Target for Expense Savings; Management Now Expects $150 to $170 Million in Annualized Cost Savings by H1/2023 versus Stated Target of $60 to $80 Million Reiterating Adjusted EBITDA Profitability Run Rate by the End of Fiscal H1 2023 Remains #1 Canadian LP in High Margin Global Medical Cannabis Revenues; International Medical Revenue Increased 55% from Q3 2021 Strong balance sheet; Early Repurchase of... Read More

Aurora Cannabis Inc. (the "Company" or "Aurora" ) (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced it has completed its previously announced acquisition of TerraFarma Inc. (parent company of Thrive Cannabis) (" Thrive ") (the " Transaction ") for aggregate initial... Read More

Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today that it has scheduled a conference call to discuss the results for its third quarter fiscal year 2022 on Thursday, May 12, 2022 at 5:00 p.m. Eastern Time | 3:00 p.m.... Read More

Thrive's highly experienced and trusted cannabis team in craft cultivation, product innovation, and operational execution will lead Aurora's Canadian recreational business Expands Aurora's brand offering with Greybeard, an award-winning, super-premium, high margin brand regarded for its budtender appreciation Transaction is... Read More

Global Cannabis Net Revenue of $60.6 Million Adjusted EBITDA Improved by 22% to a loss of $9.0 Million versus Q1 2022 Company Reaffirms Goal of Adjusted EBITDA Profitability by H1/2023 Transformation Plan Ahead of Schedule; Company Now Expects to Realize Upper End of $60 to $80 Million Range in Total Cost Savings by H1/2023;... Read More

• Believed to be the largest shipment of medical cannabis to Israel to-date • Aurora continues to advance strategic leadership in the global cannabinoid industry Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the... Read More

Newly created directorship to be filled by Chitwant Kohli, Senior Financial Executive Aurora Cannabis Inc. (the " Company " or " Aurora ") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the appointment of Chitwant Kohli to the Company's Board of Directors (the "Board"), effective today. This is a newly added position that expands the Board to nine members, seven... Read More

Licensing deal set to assist in the advancement of research and development for cannabinoid biosynthesis Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) ("Aurora"), the Canadian company defining the future of cannabinoids worldwide, together with 22nd Century Group, Inc. (NASDAQ: XXII) ("22nd Century") announced today a... Read More

Aurora Cannabis Inc. (the " Company " or " Aurora ") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, is pleased to acknowledge the Company's increased ranking in The Globe and Mail's 2021 annual Report on Business review of Corporate Boards, known as Board Games. As recognized in... Read More

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced a renewed sponsorship of Cannabis Amnesty in support of their advocacy work, calling for blanket pardons to all individuals for the offence of simple possession of cannabis. The sponsorship will... Read More

Genetics and licensing business will be led by new hire, Casey Whelan , VP, Genetics Business Development Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced the naming of the Company's new genetics licensing business... Read More

Aurora Cannabis Inc. (the " Company " or " Aurora ") (NASDAQ: ACB) (TSX: ACB) the Canadian company defining the future of cannabinoids worldwide, is pleased to announce the voting results from its Annual General Meeting of Shareholders (the " Meeting ") held on Friday, November 12, 2021 by virtual webcast. The total number of... Read More

Transformation Plan On Track; Actions Taken-to-Date Have Driven Over $33 Million in Annualized Run-Rate Cost Savings Total Cannabis Net Revenue, Net of Provisions, Grew ~10% to $60.1 million Compared to $54.8 Million in Q4 2021 Adjusted EBITDA Excluding Restructuring Costs Improved by $4.0 million to a loss of $11.5 million... Read More

First Federally Regulated Recreational Market in Europe and Largest Outside of Canada Aurora Cannabis Inc. (the " Company " or " Aurora ") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced that Aurora Nederland B.V., a wholly owned indirect subsidiary of the Company,... Read More

Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today that it has scheduled a conference call to discuss the results for its first quarter fiscal year 2022 on Tuesday, November 9, 2021 at 5:00 p.m. Eastern Time | 3:00 p.m.... Read More

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced a New Acre Project sponsorship to support ALUS. The commitment is intended to fund environmental programs in the communities where Aurora facilities are located. The sponsorship creates shared... Read More

Bidiol is the only full-spectrum cannabis oil that is fully produced domestically Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, has launched Bidiol, the first medical cannabis oil in Uruguay that is wholly produced domestically. The CBD oil is available in 3%... Read More

#1 Canadian LP in Global Medical Cannabis; Total Medical Cannabis Net Revenue Rose 9% Compared to Prior Year; Strong Adjusted Gross Margin before FVA of 68% Business Transformation Plan on Track; Reiterates Annual Cost Savings of $60 Million to $80 Million , Providing Clear Pathway to Adjusted EBITDA Profitability Balance Sheet Remains Strong with $440.9 Million of Cash at June 30, 2021 ; Working Capital Improves by $404.3... Read More

Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today that it has rescheduled its conference call to discuss the results for its fourth quarter and full fiscal year 2021 to Monday, September 27, 2021 at 5:00 p.m. Eastern Time | 3:00 p.m. Mountain Time . The Company will report its financial results for the fourth quarter... Read More

Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today that it has scheduled a conference call to discuss the results for its fourth quarter and full fiscal year 2021 on Tuesday, September 21, 2021 at 5:00 p.m. Eastern Time | 3:00 p.m. Mountain Time . The Company will report its financial results for the fourth quarter and... Read More

Distinguished senior healthcare executive, Theresa Firestone , to fill newly added position Aurora Cannabis Inc. (the " Company " or " Aurora ") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the appointment of Theresa Firestone to the Company's Board of Directors (the "Board"), effective today. This is a newly created directorship that expands the Board to nine... Read More

Shipment is part of the Company's strategy to advance its leadership in the global cannabinoid space Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the delivery of a cannabis shipment worth nearly C$8 million , in one of the largest single shipments of cannabis that Israel has received. The sale is a significant... Read More

First ever adult-use cultivars Aurora has commercialized from Aurora Coast R&D facility Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the launch of three new proprietary cultivars under the Company's premium adult-use cannabis brand San Rafael '71: Stonefruit Sunset, Lemon Rocket and Driftwood Diesel. Guided by consumer insights to identify... Read More

Full Repayment of Credit Facility Results in Principal and Interest Savings of ~$25 Million In the Next Year Aurora Cannabis Inc. (the " Company " or " Aurora ") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today that it has completed the restructuring of its balance... Read More

Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced that management will participate in three upcoming investor conferences. From June 1 -2, 2021 , Miguel Martin , CEO and Glen Ibbott , CFO will participate in the Jefferies Virtual Healthcare Conference. The Company will host virtual one-on-one investor meetings. On... Read More

The Company's patented technology expected to be key to commercial success in cannabinoid biosynthesis Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the launch of a dedicated Science & Innovation business group, with the aim of commercializing... Read More

Aurora Cannabis Inc. (the " Company " or " Aurora ") (NASDAQ | TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced that it has completed the transfer of its stock exchange listing to The Nasdaq Global Select Market ("Nasdaq") from the New York Stock Exchange ("NYSE") after the market close today. The Company's common stock will begin trading as a Nasdaq-listed security at market open on... Read More

Aurora Cannabis Inc. (the "Company" or "Aurora") (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, has filed a prospectus supplement establishing a new at-the-market equity program (the "ATM Program") that allows the Company to issue and sell up to U.S. $300 million of common shares in the capital of the Company (the "Common Shares") from treasury to the public, from time to time, at... Read More

Aurora Germany GmbH, a subsidiary of Aurora Cannabis Inc. (the " Company " or " Aurora ") (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, and Grow Group PLC ("Grow"), a biopharmaceutical company focused on improving access to cannabis-based medicines in the United Kingdom ("UK"), today announced the extension of their long-standing strategic relationship by signing a two-year... Read More

Aurora Cannabis Inc. (the "Company" or "Aurora") (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced that the Company will be participating at the BMO Capital Markets 16 th Annual Farm to Market Virtual Conference. Chief Executive Officer, Miguel Martin , and Chief Financial Officer, Glen Ibbott , will be conducting virtual one-on-one meetings with investors throughout... Read More

Domestic Medical Net Revenue Steady at $26.9 Million Strong International Medical Net Revenue of $9.4 Million Total Cannabis Net Revenue, Excluding Provisions, of $58.4 Million Business Transformation Plan Continues, Management Expects to Deliver Incremental Cost-Saving Measures of $60 Million to $80 Million Annually Balance Sheet Remains Strong with ~$525 Million of Cash on Hand at May 12, 2021 Lead Independent Director... Read More

NYSE | TSX: ACB EDMONTON, AB , April 30, 2021 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today that it has scheduled a conference call to discuss the results for its third quarter fiscal year 2021 on Thursday, May 13, 2021 at 5:00 p.m. Eastern Time . Miguel Martin , Chief Executive Officer, and Glen Ibbott ,... Read More

Aurora Cannabis Inc. (the " Company " or " Aurora ") (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced it has filed a new preliminary short form base shelf prospectus (the "Base Shelf Prospectus") with securities regulators in each of the provinces of Canada , except Quebec , and a corresponding shelf registration statement on Form F–10 (the "Registration Statement")... Read More

Total Cannabis Net Revenue of $70.3 Million , Excluding Provisions of $2.7 Million , Up 11% over Q2 2020 Medical Cannabis Net Revenue of $38.9 Million , Up 42% Versus Q2 2020, Driven by a 562% Increase in High Margin International Medical Sales Adjusted EBITDA Loss, excluding Provisions and Termination Costs, of $12.1 Million Represents an Improvement of $53.1 Million Over Q2 2020; Current Loss Triggered by Several Decisions... Read More

Aurora Cannabis Inc. (the "Company" or "Aurora") (NYSE: ABC) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today that it has scheduled a conference call on Thursday, February 11, 2021 at 5:00 p.m. Eastern Time to discuss the results for its fiscal year 2021 second quarter ended December 31, 2020 . Miguel Martin , Chief Executive Officer, and Glen Ibbott , Chief Financial Officer,... Read More

Broadest Medical Cannabis Product Range in Australian Market Aurora Cannabis Inc. (the "Company" or "Aurora") (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced it has entered into a strategic agreement with MedReleaf Australia ("MedReleaf"). The companies have signed a five-year supply agreement, which provides for MedReleaf to act as the exclusive supplier in... Read More

Aurora Cannabis Inc. (the "Company" or "Aurora") (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the "Offering") of units of the Company (the "Units") for total gross proceeds of US$137,940,000 . The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold... Read More

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE | TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000. The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to... Read More